Xenon Inhalation for Treatment of Panic Disorder

A Double-Blind, Randomized, Placebo-Controlled Trial of Xenon Inhalation for Treatment of Patients With Panic Disorder

Status

UNKNOWN

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04432155

Enrollment

200

Registered

2020-06-16

Start date

2021-06-30

Completion date

2021-12-31

Last updated

2021-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Panic Disorder

Brief summary

This study is a double-blind, randomized, placebo-controlled, clinical trial in parallel groups in patients with panic disorder.

Interventions

DRUGXenon

30% xenon, 30% oxygen, and 40% nitrogen

DRUGPlacebo

30% oxygen, and 70% nitrogen

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Primary diagnosis of panic disorder according to DSM-5. * Male and female patients ≥18 years of age.

Exclusion criteria

* History of schizophrenia, bipolar and other psychotic disorders. * Patients with underlying pulmonary disease, chronic obstructive pulmonary disease (COPD), asthma, severe lung disease and/or baseline oxygen saturations \<92% or any other respiratory conditions / diseases that may affect the respiratory function. * Currently undergoing targeted empirically-driven psychotherapy for panic disorder or panic disorder-related symptoms. * Currently undergoing exposure-based psychotherapy for any condition.

Design outcomes

Primary

Measure	Time frame	Description
PDSS	Baseline to Week 6	Panic Disorder Severity Scale

Secondary

Measure	Time frame	Description
PHQ-9	Baseline to Week 6	Patient Health Questionnaire-9

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026